title: SAPHO syndrome with unusual cutaneous manifestations treated successfully with etanercept.
authors.forename: Jaime
authors.initials: J
authors.lastname: Vilar-Alejo
authors.forename: Luis
authors.initials: L
authors.lastname: Dehesa
authors.forename: Pilar
authors.initials: P
authors.lastname: de la Rosa-del Rey
authors.forename: Javier
authors.initials: J
authors.lastname: Novoa-Medina
authors.forename: Pedro
authors.initials: P
authors.lastname: Valerón Almazán
authors.forename: Néstor
authors.initials: N
authors.lastname: Santana Medina
authors.forename: Jesús
authors.initials: J
authors.lastname: Bastida
mesh_terms: D020083:Acquired Hyperostosis Syndrome / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000068800:Etanercept; D005499:Folliculitis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011711:Pyoderma / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept